This data is for laboratory research purposes only. Not for human or animal consumption.
What is CJC-1295 with DAC?
CJC-1295 with DAC is a long-acting GHRH analogue distinct from the no-DAC variant (Modified GRF 1-29) by the addition of a Drug Affinity Complex (DAC) — a chemical modification that binds the peptide to serum albumin and dramatically extends its half-life from approximately 30 minutes to 6-8 days.
Mechanism of Action
The DAC linker is a maleimidopropionic acid moiety conjugated to the lysine residue at position 30 of the GHRH(1-29) sequence. Upon administration, it forms a covalent disulfide bond with circulating albumin, creating a "depot" effect that maintains receptor-active GHRH analogue in circulation for days. This results in sustained, non-pulsatile elevation of growth hormone secretion at the pituitary level.
Observed Laboratory Results
- Half-life ~6-8 days versus ~30 minutes for Modified GRF (1-29)
- Sustained IGF-1 elevation with weekly subcutaneous dosing
- Continuous, non-pulsatile GH elevation — distinguishes it from short-acting GHRPs
- Pharmacokinetic profile supports once-weekly dosing in research protocols
Comparison to No-DAC CJC-1295
The no-DAC variant (Modified GRF 1-29) preserves the natural pulsatile GH release pattern, while the DAC variant produces continuous elevation. Researchers select between the two based on whether pulsatile or sustained GH exposure is the desired pharmacological model.